Patients:
10 patients were considered in this study. Patients included in the
study were candidate for allogeneic hematopoietic stem cell
transplantation with a donor with DNAM-1 above 8 ng / ml. Five patients
were in the MSC pulse HSC injection group and five patients in no MSC
group. A total of 5 men and 5 women were enrolled. The mean age of the
patients in the MSC recipient group was 27.8 + 8.49 and in the
non-recipient group was 36 + 12.76. The MSC recipient group consisted of
2 males and 3 females and the non-MSC recipient group consisted of 3
males and 2 females. All patients underwent BU/FU Myeloablative
chemotherapy regimen including busulfan 0.8 mg/kg every 6 hours for 4
days and fludarabine 30 mg/m2 of body surface (IV) for 5 days.
Cyclosporine and methotrexate were considered as a prophylaxis regimen
for patients with GvHD. CysA was administered to patients at a dose of 3
mg/kg/day a day before transplantation (day -1). The duration of
prophylactic effect of cyclosporine was 6 months and in the absence of
symptoms in 3 months, the dose was reduced. The initial dose of MTX was
+10 mg / m2 on day +1 and then +6 mg / m2 on days +3, +6 and +11.
Mesenchymal stem cells were injected into the MSC recipient group 1 hour
before the injection of hematopoietic stem cell transplantation and 24 h
after transplantation. The dose of BM-MSC for injection was
1-2×106 cell/kg (Table 1,2).